Abstract
Clozapine, an atypical antipsychotic, is a dibenzodiazepine derivative and its therapeutic effects are probably mediated by dopaminergic and serotonergic activity. In accordance to several studies, it appears to be the most effective antipsychotic drug for treatment-resistant schizophrenia. Moreover, clozapine appears to be particularly beneficial in patients with schizophrenia who are suicidal and in those with comorbid substance use disorder. However, despite its efficacy, the general use of clozapine in clinical practice is somewhat limited because of the risk of several serious adverse effects such as agranulocytosis and thromboembolism. Clozapine may be associated with fatal myocarditis and cardiomyopathy in physically healthy young adults. Consequently, the FDA and the drug's manufacturer have strengthened warnings to include that a potentially fatal myocarditis may occur when taking clozapine. In the present paper the literature on clozapine-related myocardis will be reviewed and practical advice will be given concerning the diagnosis and management of such potentially fatal adverse effect.
Keywords: Clozapine, myocarditis, cardiomyopathy schizophrenia, heart failure
Current Drug Safety
Title:Update on the Adverse Effects of Clozapine: Focus on Myocarditis
Volume: 7 Issue: 1
Author(s): Domenico De Berardis, Nicola Serroni, Daniela Campanella, Luigi Olivieri, Francesca Ferri, Alessandro Carano, Marilde Cavuto, Giovanni Martinotti, Alessandra Cicconetti, Monica Piersanti, Francesco Saverio Moschetta and Massimo Di Giannantonio
Affiliation:
Keywords: Clozapine, myocarditis, cardiomyopathy schizophrenia, heart failure
Abstract: Clozapine, an atypical antipsychotic, is a dibenzodiazepine derivative and its therapeutic effects are probably mediated by dopaminergic and serotonergic activity. In accordance to several studies, it appears to be the most effective antipsychotic drug for treatment-resistant schizophrenia. Moreover, clozapine appears to be particularly beneficial in patients with schizophrenia who are suicidal and in those with comorbid substance use disorder. However, despite its efficacy, the general use of clozapine in clinical practice is somewhat limited because of the risk of several serious adverse effects such as agranulocytosis and thromboembolism. Clozapine may be associated with fatal myocarditis and cardiomyopathy in physically healthy young adults. Consequently, the FDA and the drug's manufacturer have strengthened warnings to include that a potentially fatal myocarditis may occur when taking clozapine. In the present paper the literature on clozapine-related myocardis will be reviewed and practical advice will be given concerning the diagnosis and management of such potentially fatal adverse effect.
Export Options
About this article
Cite this article as:
De Berardis Domenico, Serroni Nicola, Campanella Daniela, Olivieri Luigi, Ferri Francesca, Carano Alessandro, Cavuto Marilde, Martinotti Giovanni, Cicconetti Alessandra, Piersanti Monica, Saverio Moschetta Francesco and Di Giannantonio Massimo, Update on the Adverse Effects of Clozapine: Focus on Myocarditis, Current Drug Safety 2012; 7 (1) . https://dx.doi.org/10.2174/157488612800492681
DOI https://dx.doi.org/10.2174/157488612800492681 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Long-Term Effects of Perinatal Glucocorticoid Treatment on the Heart
Current Pediatric Reviews From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Halving Your Cake and Eating it, Too: A Case-based Discussion and Review of Metabolic Rehabilitation for Obese Adults with Diabetes
Current Diabetes Reviews Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions
Current Cardiology Reviews Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets Lung Ultrasound in the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Giant Pulmonary Artery Aneurysm Secondary To Patent Ductus Arteriosus: A Case Report
Current Cardiology Reviews Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?
Current Cardiology Reviews Molecular Pathologies of and Enzyme Replacement Therapies for Lysosomal Diseases
CNS & Neurological Disorders - Drug Targets Complications of the Chest Wall and the Respiratory System After Surgery and Functional Performance
Current Respiratory Medicine Reviews Expression of microRNAs (133b and 138) and Correlation with Echocardiographic Parameters in Patients with Alcoholic Cardiomyopathy
MicroRNA Amyloid Formation by Transthyretin: From Protein Stability to Protein Aggregation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The GH/IGF-1 Axis and Heart Failure
Current Cardiology Reviews Neuroprotection and Sex Steroid Hormones: Evidence of Estradiol- Mediated Protection in Hypertensive Encephalopathy
Mini-Reviews in Medicinal Chemistry Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy
Current Gene Therapy